How your patients and hospitals are impacted
MBLs-producing bacteria are on the rise.1 Their epidemiology is global and they are spreading, representing a significant challenge for clinical management and public health.1,2
The impact of delayed, inappropriate treatment of MBL-producing bacteria3-6
Timely, appropriate treatment, based on local epidemiology and risk factors for metallo-β-lactamases (MBL)-producing pathogens is vital to improve patient and healthcare-associated outcomes.3-7
Dr Beatrice Grabein:Reasons why you should be aware of MBLs
Dr Grabein examines the significant patient burden associated with MBL-producing bacteria.
To help you identify these patients earlier, some of the key patient risk factors associated with infections caused by MBL-producing Enterobacterales are highlighted below.
Patient risk factors for infections caused by MBL-producing Enterobacterales are largely the same as risk factors for infections caused by other carbapenemase-producing Enterobacterales and include:
8-10
Travel to/from a country endemic to MBL production
Prior exposure to antibiotics
Longer ICU stay
Comorbidities
Important predictors of MBL infections:
Prior use of carbapenems
Presence of indwelling catheter
Dr Beatrice Grabein: How to manage infections caused by MBL-producing Enterobacterales
Dr Grabein discusses a case study of a patient who had an infection caused by an MBL-producing pathogen. She takes us through the patient risk factors, the diagnosis and detection of an MBL, and the patient outcomes.
